Global Immune Checkpoint Inhibitors Market Research Report 2022

Immune checkpoints are proteins that play an important role in regulating the immune system. In cancer, the immune checkpoints are activated to suppress the anti-tumor activity of the immune system thereby suppressing the immune response against the cancer cells. The study of these proteins and pathways has led to the development of a number of immune checkpoint inhibitors as therapies against cancer. Initial preclinical studies showed that antibody blockade of the immune checkpoint molecule CTLA-4 resulted in successful anti-tumor immune responses in the murine cancer models. This was then followed by studies targeting the PD-1/PD-L1 pathway. Ipilimumab and Yervoy were the first immune checkpoint inhibitors introduced in the market. With the promising results of Yervoy, several anti-PD-1 and anti-PD-L1 antibodies have been developed. Although there are number of other checkpoints that have been studied, such as LAG-3 and TIM-3, the only approved immune checkpoint inhibitors include CTLA-4, PD-1 and PD-L1.
Due to the COVID-19 pandemic, the global Immune Checkpoint Inhibitors market size is estimated to be worth US$ 12550 million in 2021 and is forecast to a readjusted size of US$ 36030 million by 2028 with a CAGR of 16.1% during the forecast period 2022-2028. Fully considering the economic change by this health crisis, the Europe Immune Checkpoint Inhibitors market is estimated at US$ million in 2022, while the United States and China are forecast to reach US$ million and US$ million by 2028, respectively. The proportion of the United States is % in 2022, while Chinese percentage is %, and it is predicted that China market share will reach % in 2028, trailing a CAGR of % through the analysis period. As for the Europe Immune Checkpoint Inhibitors landscape, Germany is projected to reach US$ million by 2028. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.
PD-1/PD-L1 accounting for % of the Immune Checkpoint Inhibitors global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Lung Cancer segment is altered to an % CAGR throughout this forecast period and will hold a share about % in 2028.
The global major manufacturers of Immune Checkpoint Inhibitors include Bristol Myer Squibb, AstraZeneca, Merck, Roche / Genentech, Ono Pharmaceutical, Regeneron, Innovent, Hengrui Medicine and Junshi Biosciences. etc. In terms of revenue, the global 3 largest players have a % market share of Immune Checkpoint Inhibitors in 2021.
This report focuses on Immune Checkpoint Inhibitors volume and value at the global level, regional level, and company level. From a global perspective, this report represents overall Immune Checkpoint Inhibitors market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan, etc.
Global Immune Checkpoint Inhibitors Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2017 to 2028. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Segment by Type
PD-1/PD-L1
CTLA-4
Segment by Application
Lung Cancer
Colorectal Cancer
Breast Cancer
Prostate Cancer
Melanoma
Blood Cancer
Other
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
By Company
Bristol Myer Squibb
AstraZeneca
Merck
Roche / Genentech
Ono Pharmaceutical
Regeneron
Innovent
Hengrui Medicine
Junshi Biosciences